Skye high on Japanese PhIII flutiform results
This article was originally published in Scrip
Executive Summary
SkyePharma and its Japanese partner Kyorin Pharmaceuticals have announced that asthma drug flutiform (fluticasone propionate plus formoterol fumarate) has met its primary endpoints in two Phase III studies in Japan. With a Japanese regulatory filing now likely before March 2013, SkyePharma's share price increased 11% to 77.74p when the news broke on 22 June.